AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
139.93
-6.28 (-4.29%)
Jun 26, 2025, 11:26 AM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
54.98B
Revenue Growth
+15.48%
P/S Ratio
3.94
Revenue / Employee
583.05K
Employees
94,300
Market Cap
216.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
AstraZeneca News
- 2 days ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 2 days ago - AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. - WSJ
- 2 days ago - US approves AstraZeneca, Daiichi's treatment for lung cancer - Reuters
- 2 days ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 6 days ago - Is the Market Bullish or Bearish on AstraZeneca? - Benzinga
- 9 days ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC
- 12 days ago - 5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List - Seeking Alpha
- 12 days ago - AstraZeneca in deal with China firm worth up to £4bn - This is Money